论文部分内容阅读
目的探讨阿托伐他汀常规剂量治疗对不稳定型心绞痛(UAP)患者经皮冠状动脉介入术(PCI)后,心肌损伤的标记物血清肌酸磷酸激酶同功酶(CK-MB)、血浆肌钙蛋白Ⅰ(cTnI)及炎症反应标志物超敏C反应蛋白(hs-CRP)的变化。方法根据UAP患者PCI术前4周是否持续服用阿托伐他汀20mg/d分为试药组和对照组,于术前和术后8h、24h抽取肘静脉血检测血浆CK-MB、cTnI和hs-CRP。结果PCI术后两组心肌损伤及炎症反应的标记物均有不同程度升高,但试药组CK-MB、cTnI、hs-CRP水平显著低于对照组(均P<0.01)。结论UAP患者在PCI术前4周持续口服阿托伐他汀20mg/d能明显减少PCI术对UAP患者造成的心肌损伤及炎症反应。
Objective To investigate the effects of conventional atorvastatin treatment on serum creatine phosphokinase isoenzyme (CK-MB), plasma creatinine Changes of cTnI and hs-CRP, a marker of inflammation. Methods According to whether UA patients took 20 mg of atorvastatin 20 mg once daily for 4 weeks before PCI and divided them into experimental group and control group, elbow vein blood was collected before and 8h and 24h after operation to measure plasma CK-MB, cTnI and hs -CRP. Results The levels of CK-MB, cTnI and hs-CRP in myocardial injury and inflammatory response in both groups were all increased to some extent after PCI. The levels of CK-MB, cTnI and hs-CRP in the two groups were significantly lower than those in the control group (all P <0.01). Conclusions Continuous oral administration of atorvastatin 20 mg / d 4 weeks before PCI in UAP patients can significantly reduce myocardial injury and inflammatory response in UAP patients.